Immunotherapeutic Intervention against Sarcomas by Pedrazzoli, Paolo et al.
Journal of Cancer 2011, 2 
 
 
http://www.jcancer.org 
350 
J Jo ou ur rn na al l   o of f   C Ca an nc ce er r   
2011; 2:350-356 
Review 
Immunotherapeutic Intervention against Sarcomas 
Paolo Pedrazzoli1,4, Simona Secondino1, Vittorio Perfetti1, Patrizia Comoli2, Daniela Montagna3  
1.  SC Oncologia, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy  
2.  Onco-ematologia Pediatrica, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy 
3.  Dipartimento di Scienze Pediatriche, Università di Pavia, Pavia, Italy, Fondazione IRCCS Policlinico San Matteo 
4.  Gruppo Italiano Trapianto di Midollo, Cellule Staminali Emopoietiche e Terapia Cellulare (GITMO)  
 Corresponding author: Paolo Pedrazzoli, MD. SC Oncologia Fondazione IRCCS Policlinico S. Matteo, Piazzale Golgi, 19 – 
27100 Pavia, Italy. p.pedrazzoli@smatteo.pv.it 
© Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/ 
licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. 
Received: 2011.05.02; Accepted: 2011.06.03; Published: 2011.06.13 
Abstract 
Advances in systemic therapy for sarcoma have produced, over the last two decades, 
relatively  short-term  benefits  for  the  majority  of  patient.  Among  the  novel  biologic 
therapeutics that will likely increase our ability to cure human cancer in the years to 
come, immunotherapy is one of the most promising approaches. While past attempts to 
use immunotherapy have failed to dramatically shift the paradigm of care for the treat-
ment of patients with sarcoma, major advances in basic and translational research have 
resulted, in more recent years, in clinical trial activity that is now beginning to generate 
promising results. However, to move from “proof of principle” to large scale clinical ap-
plicability, we need well-designed, multi-institutional clinical trials, along with contin-
uous laboratory research to explore further the immunological characteristics of indi-
vidual sarcoma subtypes and the consequent tailoring of therapy. 
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Introduction 
Sarcomas constitute an extremely heterogeneous 
group of diseases, both in terms of histology and of 
biological and clinical behaviour [1]. Progress in the 
systemic treatment of sarcoma has been frustratingly 
slow. Prognosis of patients with metastatic or recur-
rent disease is poor and most of them will die from 
tumor progression. In such patients, with significant 
differences depending on histology subtype and age 
at disease onset, the overall median survival is around 
one year and about 10% of cases are alive at 5 years. 
Treatment of patients failing conventional treatments 
is  mainly  palliative  as  so  far  novel  therapeutic  ap-
proaches have not had a significant impact, with the 
exception of GIST, on the prognosis of these patients. 
This is in contrast with major advances in the under-
standing of the biology of this group of diseases. 
Immunotherapy  has  long  been  discussed  as  a 
promising method for the treatment of patients with 
solid tumors but thus far its exact role in sarcoma re-
mains to be defined. Previous reports have suggested 
that  immune-based  treatments  may  be  effective  in 
sarcoma, but such approaches have not yet become 
part of standard clinical practice. We now know that 
some promising targets for immunotherapy including 
cancer testis antigens are frequently expressed in cer-
tain  sarcoma  subtypes.  [2,3].  Here  we  review  prior 
trials  of  immunotherapy  including  nonspecific  im-
munomodulators,  vaccines,  and  adoptive  T-cell 
therapy. 
Nonspecific Immunomodulation  
Nonspecific  immunomodulation  refers  to  ap-
Ivyspring  
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proaches of therapy aimed to induce antitumor im-
munity without exposing the patient to a target mol-
ecule.  
Six sarcoma patients were included in one early 
high-dose interleukin 2 (IL-2) trial used in combina-
tion with limphokine-activated killer (LAK) cells [4]. 
None  of  the  patients  responded.  More  recently, 
high-dose  IL-2  was  given  in  a  pediatric  population 
including 4 patients with osteosarcoma and 2 patients 
with Ewing’s sarcoma [5]. Two osteosarcoma patients 
had  complete  responses  (CR)  that  were  durable, 
which  represents  an  encouraging  finding  that  war-
rants  more  investigation  focused  on  this  sarcoma 
subtype.  
Muramyl  tripeptide  phosphatidylethanolamine 
(MTP) is a synthetic analogue of a bacterial cell wall 
that has been studied clinically as a nonspecific im-
mune  modulator  (Bacillus  Calmette–Guerin).  Based 
on  early  studies  of  a  potential  benefit  of  liposomal 
MTP  in  sarcoma  [6,7],  the  Children's  Oncology 
Group's  Intergroup-0133  conducted  a  randomized 
trial in patients with newly diagnosed osteosarcoma. 
The study showed that ifosfamide added to the bene-
fit seen with cisplatin and doxorubicin in the adjuvant 
setting, but only when the ifosfamide was given with 
liposomal  MTP  [8].  A  subsequent  report  suggested 
that improvements in outcomes may also be seen in 
patients with metastatic disease although this analysis 
was  not  powered  to  demonstrate  a  statistically  sig-
nificant benefit in either event-free or overall survival 
[9]. To date, liposomal MTP has not secured FDA ap-
proval  but  is  available  at  a  number  of  centers  for 
compassionate use. 
Since  the  seventies  interferon  (IFN)  has  been 
employed  in  several  sarcoma  subtypes,  particularly 
osteosarcoma,  with  contrasting  results.  Published 
studies (10-15, summarized in table 1) do not allow to 
draw  conclusion  on  the  potential  benefit  of  IFN  in 
patients with sarcoma. In patients with localized os-
teosarcoma,  who  have  had  a  good  histological  re-
sponse to neoadjuvant chemotherapy, the European 
and  American  Osteosarcoma  Study  Group  trial  is 
conducting  a  randomized  trial  (EURAMOS  1)  of 
postoperative systemic therapy consisting of metho-
trexate,  doxorubicin,  and  cisplatin  with  or  without 
pegylated IFN α-2b. The pegylated preparation of IFN 
α has an extended half-life and consequently can be 
administered less frequently with higher dose deliv-
ery. The results of this study will help to define the 
role of IFN in the adjuvant treatment of osteosarcoma. 
Vaccine Trials 
Vaccines  expose  patients  to  tumor  antigens  in 
order to evoke an antitumor immune response usu-
ally in the presence of adjuvant and occasionally in 
combination with immunomodulation [3,16]. In sar-
coma  patients,  a  number  of  small  trials  have  been 
conducted using a variety of different vaccines, some 
with targeted well-defined antigens, others have tar-
geted tumor lysate (summarized in table 2). In  one 
trial [17], patients received an intradermal injection of 
irradiated  autologous  tumor  cells  along  with  either 
IFN gamma or GM-CSF as an adjuvant. Median sur-
vival  was  doubled  among  patients  who  were  de-
layed-type hypersensitivity (DTH) skin test respond-
ers compared to those who were DTH nonresponders, 
but no measurable responses were reported. Among 
10 pediatric patients treated with the same vaccina-
tion approach, one patient with fibrosarcoma had a 
partial response to the treatment which included the 
CR of several sizable pulmonary metastases [18]. 
 
 
 
 
 
Table 1: Reports of nonspecific immunomodulation with interferon (IFN) in sarcoma 
Treatment  # pts/Histology  Clinical setting  Outcome  Reference 
Leukocyte IFN  3 / osteosarcoma  Metastatic disease  2/3 partial responses  Ito, 1980 [10] 
r-IFN alfa-2a  20 / bone sarcomas  Advanced disease   3/20 short-lasting partial re-
sponses 
Edmonson,1987 [11] 
IFN beta  158 / osteogenic sarcoma  Adjuvant  74% 2.5 year disease free  Winkler, 1984 [12] 
r-IFN alfa-2b  1 / clear cell sarcoma  Metastatic disease  CR lasting 17 mo  Steger, 1991 [13] 
Leukocyte IFN alfa  19 /osteosarcoma  Adjuvant  12/19 5-year disease free  Strander, 1995 [14] 
r-IFN alfa  178 /osteosarcoma  Adjuvant  39% 10 year recurrence-free sur-
vival 
Muller, 2005 [15] 
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Table 2: Reports of vaccine-based studies in sarcoma 
Vaccine   # pts/Histology/clinical setting  Outcome   Reference  
Irradiated autologous tumor cells  16/variuos pediatric / 
advanced disease 
Improved survival in skin test responders 
(16.6 vs 8.2 mo). No tumor response  
Dillmann, 2004 [17] 
Dendritic cells pulsed with Tumor 
lysate  
10/various pediatric/  
advanced disease 
One measurable response   Geiger, 2001 [18] 
DC pulsed with tumor-specific pep-
tides  
16/Ewing-rhabdo/ 
Advanced, bulky 
One mixed response  
Three stable disease 
Dagher, 2002 [20] 
DC pulsed with tumor lysate (#=3) 
SYT-SSX2 or EWS-FLI-1 peptides 
(#=2)  
5/ various / 
(residual tumor post auto TX)  
One complete response 77mo+ (Ewing) 
Two stable disease  
Suminoe, 2009 [21] 
105AD7 (against CD55)   28/osteosarcoma/ advanced, 
post conventional chemother-
apy  
T cell response in vivo (13/28); 1 
long-lasting response  
Pritchard –Jones, 
2005 [23] 
 
 
 
The  largest  dendritic  cell  vaccine  trial  to  date 
enrolled 52 patients with t(2;13) or t(11;22) transloca-
tion positive, recurrent, or metastatic Ewing's sarcoma 
family of tumors or alveolar rhabdomyosarcoma [19]. 
All patients underwent prechemotherapy cell harvest 
via apheresis for potential receipt of immunotherapy. 
Following completion of  standard multimodal ther-
apy, 30 patients ultimately underwent immunother-
apy with dendritic cells pulsed with peptides derived 
from tumor-specific translocation breakpoints and E7, 
a  peptide  known  to  bind  HLA-A2.  Toxicity  was 
minimal.  Intention-to-treat  analysis  suggested  a 
longer  overall  survival  for  patients  who  received 
immunotherapy compared to all patients apheresed. 
While  the  results  provided  by  this  study  are  intri-
guing,  a  firm  conclusion  of  the  efficacy  of  this  ap-
proach  can  only  be  drawn  from  a  prospective  ran-
domized trial.  
Other series of vaccine-based treatment includ-
ing a limited number of patients have been reported 
[20-25], none providing clear evidence of a potential 
benefit of this approach in sarcoma patients.  
There is an on-going randomized placebo con-
trolled multicenter Phase II trial of a trivalent peptide 
vaccine to the gangliosides GD2, GD3, and GM2 in 
patients with advanced stage sarcoma rendered dis-
ease  free  by  surgical  resection.  These  gangliosides, 
thought to play a role in cell adhesion and cell-cell 
interactions,  may  be  expressed  in  some  sarcomas 
[26-28] and one report suggests that soft tissue sar-
coma patients develop an antibody response to GD2 
more  frequently  than  healthy  subjects  [29].  On  the 
other hand, it is worth noting that a randomized trial 
of gangliosidein in melanoma failed to demonstrate 
improvement in survival [30]. 
Adoptive T-Cell Therapy (ATCT) 
ATCT involves the expansion either ex vivo (for 
later reinfusion) or in vivo, of immune effector cells 
capable of tumor killing. This may be nonspecific, as 
in  the  case  of  allogeneic  hematopoietic  stem  cell 
transplantation  (HSCT),  or  cytokine-induced  killer 
(CIK), or may use tumor/antigen-specific ex vivo cul-
tures  or  genetically  engineered  cells  to  have  tu-
mor-directed specificity. 
Nonspecific ATCT 
Allogeneic Stem Cell Transplantation  
Evidence of an immune-mediated effect against 
sarcoma in experimental animal models of allogeneic 
HSCT has been reported since the 80’ [31,32]. Based 
on  these  preclinical  results  single  case  reports  and 
small  series  of  patients  with  sarcoma  treated  with 
allogeneic HSCT from HLA-matched sibling donors 
have been reported with contrasting results [33,34]. A 
retrospective analysis of adult patients with soft tissue 
sarcoma registered at the EBMT database [35] was not 
able to draw firm conclusions about a possible role of 
allogeneic  transplantation  in  advanced  STS,  mainly 
because  of  the  heterogeneity  of  the  patient  popula-
tion.  
Recently, Thiel et al [36] retrospectively analyzed 
data of 87 Ewing sarcoma patients from various reg-
istries  treated  with  allogeneic  HSCT  and  evaluated 
the  outcome  regarding  the  use  of  reduced-intensity 
conditioning  (RIC)  and  high-intensity  conditioning 
(HIC) regimens as well as human leukocyte antigen 
(HLA)-matched  and  HLA-mismatched  grafts.  There 
was no improvement of survival with RIC compared 
with HIC due to increased relapse incidence after RIC 
despite less transplant-related mortality (TRM) inci-
dence. HLA mismatch was not generally associated 
with a greater antitumor effect. These results suggest 
general absence of a clinically relevant Graft-versus 
Sarcoma effect. 
Allogeneic HSCT can be viewed, in perspective, 
as a platform for additional approaches of adoptive Journal of Cancer 2011, 2 
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immunotherapy [37]. The donor immune system can 
in  fact  permit  the  repeated  infusion  of  alloimmune 
lymphocytes, tumor-specific T cells or NK/CIK cells 
from the donor without risking their rejection. 
Cytokine-Induced Immune Effector Cells 
LAK  cells  are  cytotoxic  effector  lymphocytes 
whose cytolytic activities are not restricted by major 
histocompatibility complex (MHC) and have the abil-
ity to kill fresh tumor cells and NK-resistant tumor 
cell  lines  [38].  LAK  cells  are  generated  from  blood 
lymphocytes following expansion in the presence of 
IL-2  for  a  5-day  culture  period.  LAK  cells  demon-
strated potent in vitro cytotoxicity against susceptible 
tumor cells and led to the regression of established 
tumors in animal models [39-41]. In clinical studies, 
LAK cells had shown modest efficacy in solid tumors 
such as renal cell carcinoma, melanoma and hepato-
cellular carconoma [42,43] and no data are available in 
the setting of sarcoma. 
Closely related to LAK cells, CIK cells are poly-
clonal T effector cells generated in vitro by incubation 
of  peripheral  blood  lymphocytes  with  anti-CD3 
monoclonal antibody, IL-2, IL-1 alpha, and interfer-
on-gamma  [44].  This  unique  subset  of 
non-MHC-restricted CD3+CD56+ T cells was referred 
to as NK-like T cells since, similar to the NK cells, they 
do not require prior specific sensitization to induce 
the recognition of target cells. CIK cells have a high 
rate of proliferation and demonstrate a potent cyto-
lytic activity in vitro against a variety of tumor tar-
gets,  including  sarcomas  [45.46].  However,  data  on 
the efficacy of CIK cells in vivo are limited [47].  
CIK cells show only limited graft-versus-host ef-
fects  in  various  mouse  models  [48]  which  suggest 
their  potential  use  as  adoptive  immunotherapy  fol-
lowing allogeneic transplantation [49,50] i.e as an ef-
fective alternative to classic donor lymphocyte infu-
sion [51]. 
Targeted ATCT  
A strategy that has proven effective in increasing 
the efficacy of anticancer cell therapy protocols is the 
ex  vivo  identification  of  autologous  or  allogeneic 
lymphocytes with antitumour activity, which are then 
administered to cancer patients. A number of differ-
ent approaches have been so far employed to obtain 
tumor-specific T cells, such as: ex vivo selection TIL 
based on their capacity to recognize autologous tumor 
cells,  repeated  in  vitro  stimulation  with  tu-
mor-associated antigens (TAA)/whole tumor cells, or, 
more  recently,  genetic  modification  of  T-cells  using 
T-cell receptors encoding retroviruses, that can con-
vert normal lymphocytes into cells with specific an-
ti-cancer activity.  
Tumor-Infiltrating Lymphocytes 
TIL therapy can be considered a targeted T cell 
therapy as they are ex vivo selected for their capacity 
to  recognize  autologous  tumor  cells.  Transfusion  of 
TIL has emerged as the most effective treatment for 
patients  with  metastatic  melanoma,  a  decisive  im-
provement  in  their  efficacy  coming  with  the  intro-
duction of an immunodepleting preparative regimen 
given before the adoptive transfer, which resulted in 
the clonal repopulation of patients with anti-tumour T 
cells  [52].  Though  some  early  work  did  seem  to 
demonstrate that TIL can be grown in culture from 
patients with sarcoma [53,54], with variable yield, no 
clinical data are available. We believe that this may 
represent an area of future developement. 
T-Cell Lines Specific for TAA 
Over the last decade, progress in the field of bi-
otechnology  has  allowed  for  the  characterization  of 
tumor  cells,  with  identification  of  tumor-specific  or 
tumor associated antigens. However, the number of 
TAA identified so far is relatively limited if compared 
to the plethora of molecules present on tumor cells 
that may contribute to stimulate a protective immune 
response. To overcome this problem, during the past 
few years, the use of dendritic cells pulsed with whole 
tumor  cell  preparations,  to  cross-prime  cytotoxic 
T-lymphocytes (CTLs) has been investigated [55-57]. 
Montagna  et  al.  demonstrated  the  feasibility  of  ob-
taining large quantities of autologous anti-tumor spe-
cific CTLs generated by stimulation of patients’ pe-
ripheral blood mononuclear cells with dendritic cells 
pulsed with apoptotic tumor cells [58]. In a pilot study 
[59],  the  same  authors  have  shown  that  anti-tumor 
CTLs can be administered safely in patients with ad-
vanced  solid  malignancies,  including  sarcoma,  and 
can  improve  the  immunological  status  of  recipients 
against tumor. The clinical efficacy of such immuno-
therapeutic approach will be investigated further in a 
phase II study. 
Very  recently,  It  has  been  shown  that  cancer 
stem-like cells/ cancer-initiating cells of bone malig-
nant fibrous histiocytoma are recognized by autolo-
gous CTLs in the tumor microenvironment and pe-
ripheral circulating lymphocytes [60] which support 
the hypothesis that CTL-based immunotherapy could 
target cancer stem cells of bone sarcoma.  
ATCT with T-Cells Specific for Viral Antigens 
A rare example of solid cancer setting in which 
tumor-specific T cells have been employed with suc-Journal of Cancer 2011, 2 
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cess is virus-related tumors. In particular, independ-
ent phase I-II studies demonstrated that clinical and 
immunological responses can be obtained in patients 
with  radiotherapy-  and  chemotherapy-resistant, 
EBV-related  nasopharingeal  carcinoma  by  admin-
istration of EBV-specific autologous polyclonal CTL 
therapy [61-64]. No clinical data are yet available in 
the  setting  of  virus-related  sarcomas  and  this  may 
well be an area of future development in selected pa-
tients [65-66]. 
T-Cells Modified to Express Chimeric Receptors 
A  strategy  to  broaden  the  reactivity  against 
shared cancer-associated antigens present on multiple 
tumour types consists in grafting specificities for an-
tigens  expressed  on  tumour  cells  through  genetic 
manipulation [67]. Investigators have developed arti-
ficial T-cell receptors, also referred to as chimeric an-
tigen receptors, isolated from high avidity T cells that 
recognize cancer antigens, and retroviral or lentiviral 
vectors have been used to redirect lymphocyte speci-
ficity  to  these  cancer  antigens.  Clinical  studies  in 
B-cell  haematological  malignancies  [68]  and  subse-
quently  in  solid  tumors  [69-72]  demonstrated  that 
normal human lymphocytes genetically engineered to 
express a TAA, can mediate cancer regression in vivo. 
Very recently, Robbins et al [73] reported on the abil-
ity  of  adoptively  transferred  autologous  T  cells 
transduced  with  a  T-cell  receptor  (TCR)  directed 
against the cancer testis antigen NY-ESO-1 to mediate 
tumor response in metastatic synovial cell sarcoma. 
Objective clinical responses were observed in four of 
six  patients  with  synovial  cell  sarcoma  including  a 
near CR lasting 18 months. This represents the first 
demonstration of the successful treatment of a non-
melanoma tumor using TCR-transduced T cells. The 
NY-ESO-1  antigen  is  expressed  in  80%  of  synovial 
sarcoma but also in 15% to 50% of highly prevalent 
tumors that include breast, lung, prostate, and ovari-
an  cancer  [74,75].  Therefore,  effective  therapies  that 
target NY-ESO-1 could potentially be applied to the 
large population of cancer patients. 
Conclusions 
Over the years immunotherapeutic approaches 
have shown signals of great potential in selected pa-
tients with sarcoma. As an example, the dramatic re-
sponses  to  T-cell  therapy  recently  demonstrated  in 
synovial cell sarcoma. Studies like this just scratch the 
surface  of  what  might  be  feasible  for  patients  with 
sarcomas in the future, since as many as 25% of sar-
comas have reproducible genetic changes. 
To move from “proof of principle” to large scale 
clinical  applicability  we  need  well-designed,  multi-
institutional clinical trials, along with continuous la-
boratory research to explore further the immunolog-
ical  characteristics  of  individual  sarcoma  subtypes 
and the consequent tailoring of therapy. 
While past attempts to use immunotherapy have 
failed to dramatically shift the paradigm of care for 
the treatment  of patients  with  sarcoma, a great op-
portunity now exists to increase the therapeutic op-
tions available in this challenging group of diseases. 
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